Eli Lilly and Company, Becton, Dickinson and Company, Berry Global Group, Novo Nordisk A/S, and Thermo Fisher Scientific are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of companies involved in the research, development, manufacturing, and marketing of drugs and related healthcare products. Their market value is driven by factors such as clinical trial results, regulatory approvals, patent expirations, and shifts in healthcare policy and consumer demand. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE LLY traded down $85.11 during trading hours on Thursday, hitting $813.84. 9,118,393 shares of the stock were exchanged, compared to its average volume of 3,454,887. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a market cap of $771.66 billion, a PE ratio of 69.48, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company's fifty day simple moving average is $828.65 and its two-hundred day simple moving average is $817.92.
Read Our Latest Research Report on LLY
Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Becton, Dickinson and Company stock traded down $30.63 during mid-day trading on Thursday, reaching $176.46. The company had a trading volume of 7,603,491 shares, compared to its average volume of 1,765,694. Becton, Dickinson and Company has a fifty-two week low of $173.79 and a fifty-two week high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The company has a market cap of $50.67 billion, a P/E ratio of 29.18, a P/E/G ratio of 1.63 and a beta of 0.35. The business has a fifty day simple moving average of $217.21 and a 200 day simple moving average of $226.70.
Read Our Latest Research Report on BDX
Berry Global Group (BERY)
Berry Global Group, Inc. manufactures and supplies non-woven, flexible, and rigid products in consumer and industrial end markets in the United States, Canada, Europe, and internationally. The company operates through Consumer Packaging International; Consumer Packaging North America; Engineered Materials; and Health, Hygiene & Specialties segments.
Shares of BERY stock traded down $1.94 during trading hours on Thursday, hitting $67.69. 18,809,857 shares of the company's stock traded hands, compared to its average volume of 1,392,497. The stock's 50 day simple moving average is $69.03 and its 200 day simple moving average is $68.60. The stock has a market cap of $7.84 billion, a PE ratio of 16.88, a price-to-earnings-growth ratio of 1.54 and a beta of 1.14. Berry Global Group has a 12 month low of $56.96 and a 12 month high of $74.24. The company has a quick ratio of 1.09, a current ratio of 1.61 and a debt-to-equity ratio of 3.35.
Read Our Latest Research Report on BERY
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NVO stock traded down $0.63 during trading hours on Thursday, hitting $65.82. 12,803,665 shares of the company's stock traded hands, compared to its average volume of 6,178,743. The stock's 50 day simple moving average is $72.40 and its 200 day simple moving average is $88.69. The stock has a market cap of $295.36 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.
Read Our Latest Research Report on NVO
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE TMO traded down $7.74 during mid-day trading on Thursday, reaching $421.26. 1,525,534 shares of the stock were exchanged, compared to its average volume of 1,757,722. Thermo Fisher Scientific has a one year low of $409.85 and a one year high of $627.88. The stock has a 50 day simple moving average of $480.79 and a 200-day simple moving average of $524.13. The stock has a market cap of $159.02 billion, a P/E ratio of 25.49, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.
Read Our Latest Research Report on TMO
Recommended Stories
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
